-
公开(公告)号:US20230025630A1
公开(公告)日:2023-01-26
申请号:US17292891
申请日:2019-11-11
申请人: Novartis AG
发明人: Shomir GHOSH , Jason KATZ , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN
IPC分类号: C07D417/06 , C07D417/12 , C07D417/14 , C07D401/06 , A61P35/00
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20210395241A1
公开(公告)日:2021-12-23
申请号:US17252613
申请日:2019-07-02
申请人: Novartis AG
发明人: Gary GLICK , William R. Roush , Shankar VENKATRAMAN , Dong-Ming SHEN , Shomir GHOSH , Hans Martin SEIDEL , Luigi FRANCHI , David Guenther WINKLER , Anthony William OPIPARI , Jason KATZ
IPC分类号: C07D417/12 , C07D277/36 , C07C311/51 , A61K45/06
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20230031406A1
公开(公告)日:2023-02-02
申请号:US17292881
申请日:2019-11-11
申请人: Novartis AG
发明人: Shomir GHOSH , Gary GLICK , Jason KATZ , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN
IPC分类号: C07D409/12 , A61P1/00 , C07D417/12 , C07D221/16 , C07D401/12 , C07D221/18 , C07D498/04 , C07D471/04 , C07D498/20 , C07D487/04 , C07D491/04 , C07D495/04 , C07D409/14 , C07H15/26
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20220267276A1
公开(公告)日:2022-08-25
申请号:US17252623
申请日:2019-07-02
申请人: Novartis AG
发明人: Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, Jr. , William R. ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号: C07D221/16 , C07D277/36 , C07D417/12 , C07D213/75 , C07C335/42 , A61K45/06
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.
-
公开(公告)号:US20230079631A1
公开(公告)日:2023-03-16
申请号:US17662863
申请日:2022-05-11
申请人: Novartis AG
发明人: Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, JR. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号: C07D265/30 , A61P1/00 , A61P11/00 , A61P19/08 , A61P35/00 , C07C381/10 , C07D209/26 , C07D211/78 , C07D215/06 , C07D231/12 , C07D239/26 , C07D239/36 , C07D261/08 , C07D263/46 , C07D277/36 , C07D317/50 , C07D333/34 , C07D401/12 , C07D409/12 , C07D417/12
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20230051589A1
公开(公告)日:2023-02-16
申请号:US17293781
申请日:2019-11-14
申请人: Novartis AG
发明人: Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, Jr. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号: A61K31/426 , A61K45/06 , A61K31/64 , C07D307/64 , C07D277/36 , A61K31/381 , C07D333/34 , C07D409/12 , A61K31/4436 , A61K31/18 , C07C381/10 , C07D231/18 , A61K31/415 , A61K31/36 , A61K31/4406 , A61K31/47 , C07D317/62 , C07D213/71 , C07D215/36 , C07D487/04 , C07D405/12 , A61K31/4188 , A61K31/397 , C07D205/04 , C07D295/096 , A61K31/5375 , C07D207/10 , A61K31/40 , A61K31/4015 , C07D207/12 , C07D333/72 , A61K31/451 , C07D211/24 , C07D495/04 , A61K31/4365 , A61P1/00 , A61P37/06
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20230011652A1
公开(公告)日:2023-01-12
申请号:US17287834
申请日:2019-10-23
申请人: Novartis AG
发明人: William ROUSH , Shankar VENKATRAMAN , Shomir GHOSH , Dong-Ming SHEN , Jason KATZ , Hans Martin SEIDEL
IPC分类号: C07D498/20 , C07D333/50 , C07D495/04 , C07D498/04 , C07D487/04 , C07D471/04 , C07D513/04
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20230416211A1
公开(公告)日:2023-12-28
申请号:US18319630
申请日:2023-05-18
申请人: NOVARTIS AG
发明人: Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号: C07D277/36 , C07D307/64 , C07D333/34 , C07C307/06 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/79 , C07D317/62 , C07D487/04
CPC分类号: C07D277/36 , C07D307/64 , C07D333/34 , C07C307/06 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/79 , C07D317/62 , C07D487/04 , C07C335/42
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:
or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.-
公开(公告)号:US20230062815A1
公开(公告)日:2023-03-02
申请号:US17496375
申请日:2021-10-07
申请人: Novartis AG
发明人: Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, JR. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号: C07D277/36 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/64 , C07D307/79 , C07D317/62 , C07D333/34 , C07D487/04 , C07C307/06
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号:US20230024859A1
公开(公告)日:2023-01-26
申请号:US17292887
申请日:2019-11-11
申请人: Novartis AG
IPC分类号: C07D417/12 , C07D275/06 , C07D281/10 , C07D513/04 , C07D279/02 , C07D285/18 , C07D285/36 , C07D513/10 , A61K45/06 , A61P35/00
摘要: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
-
-
-
-
-
-
-
-